Tech • IA • Crypto
50 articles analyzed by AI / 181 total
OpenAI plans to invest more than $20 billion in Cerebras AI chips and will acquire an equity stake in Cerebras, marking a significant strategic hardware partnership aimed at enhancing its AI research infrastructure as of April 17, 2026.
Novo Nordisk partnered with OpenAI to revolutionize medicine discovery by leveraging AI for drug development, a collaboration announced on April 17, 2026, aiming to accelerate pharmaceutical innovation.
OpenAI launched free AI training programs in Abilene, Texas on April 17, 2026, to improve local workforce skills and promote AI literacy, expanding educational access to AI technologies.
Following its major $20 billion deal with OpenAI, AI chipmaker Cerebras filed for an IPO on April 17, 2026, signaling growth and increased public market participation partly fueled by OpenAI’s strategic investment.
OpenAI announced the departure of key executive Kevin Weil on April 17, 2026, a move that may impact the company’s strategic leadership and ongoing projects.
OpenAI plans to deploy 750 megawatts of high-speed AI compute with Cerebras Systems and will co-design future AI models for Cerebras hardware, highlighting a deep industrial partnership announced on April 17, 2026.
On April 17, 2026, OpenAI introduced a new AI model specifically tailored for biology and scientific research, focusing on advancing applications in life sciences.
OpenAI launched GPT-Rosalind, a new AI model designed to accelerate drug discovery and biology research, announced on April 17, 2026, marking its deepening involvement in life sciences.
OpenAI released GPT-5.4-Cyber, a new AI model considered more open than competitor Claude Mythos, on April 17, 2026, emphasizing enhanced cybersecurity and competitive positioning.
OpenAI announced a $20 billion purchase of Cerebras AI chips and an additional $1 billion investment in Cerebras datacenters as of April 17, 2026, representing a large-scale infrastructure expansion partnership.